(firstQuint)A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma.

 This open-label Phase 2 study will evaluate the efficacy and safety of PT2977 in patients with VHL disease who have at least 1 measurable RCC tumor.

 PT2977 will be administered orally and treatment will be continuous.

 Patients will be evaluated radiologically approximately 12 weeks after initiation of treatment and every 12 weeks thereafter while continuing in the study.

 Changes in VHL disease-associated non-RCC tumors will also be evaluated.

.

 A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma@highlight

This study is designed to investigate PT2977 as a treatment for VHL disease associated RCC.

